Cardiff Oncology, Inc.

Healthcare · Biotechnology · United States

Last price 0.912 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 70.95M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CR...